Compare Abeona Therapeutics Inc (ABEO) vs Goldman Sachs Group Inc (GS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Goldman Sachs Group Inc — how do they compare? Abeona Therapeutics Inc trades at $6.73 (market cap $373.32M), while Goldman Sachs Group Inc trades at $1,024.12 (market cap $307.69B). The key difference: Goldman Sachs Group Inc is far larger — about 824.2× Abeona Therapeutics Inc's market cap, and Goldman Sachs Group Inc pays a 1.73% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | GS | |
|---|---|---|
Market Cap | $373.32M | $307.69B |
Sector | Health | Financials |
52-Week High | $7.23 | $1.11K |
52-Week Low | $4.17 | $696.57 |
Enterprise Value | $228.22M | — |
Volume | — | 2,592,735 |
Dividend Yield | — | 1.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Goldman Sachs (GS) trades at $1,055.29, up 3.36% with a bullish technical outlook and strong fundamental performance. Recent earnings consistently beat estimates, with Q1 2026 EPS of $17.55 exceeding expectations. Revenue grew to $58.28B in 2025, and net income margin improved to 29.89%. The company is positioned to benefit from a surge in IPO activity, including leading high-profile deals like Anthropic's upcoming offering.
The stock presents a favorable risk-reward profile with a consensus price target of $1,080, implying modest upside. Key risks include volatile cash flows and high leverage, but robust investment banking pipelines and CEO optimism about market 'greed mode' support growth. Analyst sentiment is mixed but leans positive, with 40% recommending Buy.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Goldman Sachs Group Inc
The Goldman Sachs Group, Inc., a bank holding company, is a global investment banking and securities firm specializing in investment banking, trading and principal investments, asset management and securities services. The Company provides services to corporations, financial institutions, governments, and high-net worth individuals.
Read more on GS →
